Arsenal Bio
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $410M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 29.12.2024 | ARCH Ventu... | archventur... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.09.2024 | Series C | $325M | - |
| 17.10.2019 | Series A | $85M | - |
Mentions in press and media 16
| Date | Title | Description |
| 11.09.2026 | Luma перестроила модель венчурного фонда под разработку лекарств | Инвестиционная компания Luma Group завершила формирование своего первого венчурного фонда LumaBio I объемом $410 млн для вложений в биотехнологии и другие проекты в сфере наук о жизни. От обычных венчурных фондов он отличается сроком работы... |
| 01.11.2024 | The show’s not over: 2024 sees big boost to AI investment | Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Global AI deal volumes reached 1,245 during Q3 2024, a level not seen since Q1 2022 reflecting how confident and ... |
| 28.09.2024 | ARCH Venture Partners: $3+ Billion New Fund Raised To Invest In Next-Gen Biotech Companies | ARCH Venture Partners announced the closing of ARCH Venture Fund XIII, a venture capital fund with over $3 billion to support the founding and growth of early-stage biotechnology companies. ARCH invests in early-stage companies that prevent... |
| 09.09.2024 | Стартап в сфере клеточной терапии ArsenalBio привлек $325 млн | В раунде финансирования Arsenal Biosciences приняли участие новые инвесторы ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (венчурное подразделение NVIDIA), Luma Group, фонды, консультируемые T. Rowe Price... |
| 04.09.2024 | ArsenalBio Raises $325M in Series C Funding | ArsenalBio, a San Francisco, CA-based clinical stage programmable cell therapy company, raised $325M in Series C funding. The round was led by ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures, Luma Group, fu... |
| 04.09.2024 | ArsenalBio raises $325M for solid tumor CAR-T science with Regeneron and BMS in tow | Arsenal Biosciences is moving on up. The cell therapy company has added on $325 million in ammunition with big-name backers like Regeneron joining the artillery as the biotech sets out to build the biggest—and best—house on the block. “It i... |
| 04.09.2024 | ArsenalBio: $325 Million (Series C) To Enhance Programmable Cell Therapy Programs | Arsenal Biosciences, a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, announced today the closing of an oversubscribed $325 million Series C financing round. This fund... |
| 04.09.2024 | ArsenalBio Raises $325M in Series C Funding | SOUTH SAN FRANCISCO, CA, ArsenalBio, a clinical stage programmable cell therapy company has announced the close of an oversubscribed $325 million Series C financing round. >> Click here for more funding data on ArsenalBio >> To... |
| 07.09.2022 | ArsenalBio Raises $220M As Cell Therapy’s Popularity Grows | 2 Shares Email Facebook Twitter LinkedIn As innovations in cell therapy continue to grow, San Francisco-based ArsenalBio this week announced it raised a whopping $220 million in Series B funding, one of the largest rounds this year for a ce... |
| 25.10.2019 | ArsenalBio Raises $85 Million In Funding To Develop Immune Cell Therapies | ArsenalBio has raised $85 million in Series A funding to build effective and accessible programmable cell therapies. These are the details. ArsenalBio recently announced that it raised $85 million in Series A funding to build effective and ... |
Show more